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Abstract
Background: In targeted radionuclide therapy (TRT), accurate quantification using SPECT/CT images is important for
optimizing radiation dose delivered to both the tumour and healthy tissue. Quantitative SPECT images are regularly
reconstructed using the ordered subset expectation maximization (OSEM) algorithm with various compensation methods
such as attenuation (A), scatter (S) and detector and collimator response (R). In this study, different combinations of the
compensation methods are applied during OSEM reconstruction and the effect on the 177Lu quantification accuracy is
studied in an anthropomorphic torso phantom. In addition, the phantom results are reflected to (177)Lu-DOTA-Tyr3-
octreotate (177Lu-DOTATATE)-treated patient data and kidney absorbed dose estimates.
Methods: The torso phantom was imaged with nine various sized (0.4–104.4 cm3) spherical inserts, filled with known
177Lu activity ranging from 0.5 to 105.5 MBq. Images were reconstructed using OSEM algorithm using A, AR and ARS
compensation method combinations. The compensation method combinations were compared by calculating the
concentration recovery coefficient (cRC) for each insert. In addition, ten 177Lu-DOTATATE-treated patient’s post-therapy
dosimetry acquisitions were reconstructed, and the absorbed dose to kidneys was estimated.
Results: cRC values depend on the insert size for all compensation methods. AR and ARS produced significantly higher
cRC values than attenuation correction alone. There were no cRC value differences between the methods for the
smallest 1-cm-diameter insert, cRC being 0.18. However, the collimator and detector response compensation method
(R) made the 1.3-cm-diameter insert clearly visible and improved cRC estimate from 0.19 to 0.43. ARS produced slightly
higher cRC values for small- and medium-sized inserts than AR. On the patient data, a similar trend could be seen.
AR and ARS produced higher kidney activities than using attenuation correction alone; the total absorbed doses to
the right and left kidneys were on average 15 and 20 % higher for AR and 19 and 25 % higher for ARS, respectively.
The effective half-life decay estimated from time-activity curves however showed no notable difference between the
compensation methods.
Conclusions: The highest cRC values were achieved by applying ARS compensation during reconstruction. The results
were notably higher than those using attenuation correction alone. Similarly, higher activity estimates and thus higher
absorbed dose estimates were found in patient data when all compensation methods were applied. ARS improved
cRC especially in small-sized sources, and it thus might aid tumour dosimetry for 177Lu PRRT treatments.
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Background
The 177Lu-labelled somatostatin analogues (177)Lu-DOTA-
Tyr3-octreotide (177Lu-DOTATOC) and (177)Lu-DOTA-
Tyr3-octreotate (177Lu-DOTATATE) are used for peptide
receptor radionuclide therapy (PRRT) for the treatment of
neuroendocrine tumours (NETs), which are a group of
tumours characterized by overexpression of somatostatin
receptors. Although both radiopharmaceuticals have been
reported to have very high affinity to somatostatin receptors
[1] and high tumour accumulation [2], kidney doses have
also been reported to be high and widely variable between
patients [2, 3]. Therefore, patient specific post-therapeutic
dosimetry should be performed to ensure patient safety.
Dosimetry should be extended from the kidney alone to the
tumour as demonstrated in Ilan et al. [4] to further our
understanding of the PRRT dose response as well as to tar-
get the treatments to specific patients who could benefit
from them.
Absorbed dose calculation of 177Lu-labelled radiophar-
maceuticals is based on activity distribution quantification
using single photon emission imaging combined with
computed tomography (SPECT/CT). In addition to highly
ionizing beta radiation that produces about 96 % of the
absorbed dose [5], 177Lu also emits low and medium
energy γ radiations that can be imaged using a SPECT/CT
system. Activity quantification from SPECT images is not
a trivial task. Inaccuracies in image reconstruction and
thus in radionuclide uptake estimates are introduced
through photon attenuation, scattering, and collimator
blurring. Iterative reconstruction techniques allow effect-
ive methods for compensation, namely attenuation correc-
tion (A), scatter correction (S) and collimator-detector
response (R) compensation [6–8], and thus are used in
different combinations in quantitative targeted radio-
nuclide therapy (TRT) imaging.
The ordered subsets expectation maximization (OSEM)
algorithm [9] has been widely used for quantitative recon-
struction and internal dosimetry calculations. It has been
studied using different combinations of compensation
methods, and average quantification error has been
reported to be from low (1 %) to moderate (20 %) [10].
The results depend on many factors such as source size
and shape, isotope and activity concentration of source
and background, which increases complexity and also
makes comparison between published results difficult.
177Lu radionuclide quantification accuracy has not been
studied very extensively [11–14] even though a large
number of patients have been treated with 177Lu-labelled
somatostatin analogues. Recently, Sanders et.al [12] vali-
dated a 177Lu quantitative SPECT/CT imaging protocol in
vivo using urine samples, implementing the method
published earlier by Zeintl et al. [15]. In the work of
Sanders et.al, the mean error in activity concentration esti-
mated from patients using SPECT/CT was 10.1 ± 8.3 %
(range, −19.4 to 22.4 %). The activity estimates were done
at one time point after 177Lu-DOTATATE therapy injec-
tion, and no estimation was made of the effect of degraded
image statistics at later time points on the quantification
accuracy. Sanders et.al concluded that quantitative SPECT/
CT in vivo is feasible but could benefit from improved
reconstruction methods and a more sophisticated scatter
compensation method [12].
In this study, OSEM-based reconstruction package was
validated for 177Lu radionuclide using realistic anthropo-
morphic torso phantom measurements. The quantitation
accuracy of the reconstruction package was determined
using different sized spherical inserts in the torso phantom.
Concentration recovery coefficients (cRCs) were calculated
for the inserts through application of state of the art com-
pensation methods such as Monte Carlo-based scatter
correction (S), collimator-detector response (R) and CT-
based attenuation correction (A) during the reconstruction.
We also studied how different compensation combinations
affect the fundamental dosimetric parameters such as the
effective half-life and absorbed dose estimates using clinical
177Lu-DOTATATE-treated patient data.
Methods
Our study is composed of two different parts: (i) determin-
ing the 177Lu quantification accuracy of our reconstruction
package using a torso phantom and (ii) reconstruction of
patient data with different compensation combinations and
determination of absorbed dose estimates for kidneys. All
the phantom and patient data were acquired, reconstructed
and analysed in a similar way, and the details are given in
the following sections.
SPECT/CT imaging protocol
Images were acquired on a SPECT/CT system (Symbia
T2, Siemens Healthcare, Erlangen, Germany) using the
local clinical imaging protocol for 177Lu-therapy patients.
The SPECT acquisition included the following parame-
ters: 64 projections, 20 s per projection, a non-circular
step-and-shoot acquisition orbit, 128 × 128 matrix and
4.8 mm pixel size. Projection data were acquired using a
20 % energy window centred on the 208 keV photopeak
using a parallel-hole medium energy low penetration
(MELP) collimator. After the SPECT acquisition, a CT
scan was performed using the CT tube voltage of
130 keV and a quality reference tube current-time prod-
uct of 100 mAs (CareDose 4D). The calculated CTDIvol
was 10.8 mGy, and the CT scans covered one or two
SPECT field of views (40 cm per view) depending on the
case. CT data was reconstructed to 512 × 512 matrix
with 0.98 × 0.98 mm pixel size and 3.0 mm slice thick-
ness. The CT reconstruction was performed using two
different kernels: smoother kernel (B08s) for attenuation
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correction and scatter correction and sharper kernel (B35)
for volume of interest (VOI) delineation.
Image reconstruction
All images were reconstructed with an OSEM algorithm
with 15 iterations and 16 subsets. Compensations for at-
tenuation and collimator-detector response were applied
as described in [16]. Briefly, the CT attenuation map was
generated using a bilinear conversion for HU to linear
attenuation coefficient values, and collimator correction
was based on the Gaussian convolution. The scatter cor-
rection was implemented using an accelerated Monte
Carlo (MC) simulation method [17]. Because MC scatter
simulations are time-consuming, the scatter correction
was accelerated with convolution-based forced detection
and calculation of the scattering into a sparser matrix
than the resulting image. The scatter estimate was calcu-
lated for only the first two iterations, and the scattering
was modelled only during forward projection.
All SPECT reconstructions produced images with 128 ×
128 matrix with 128 slices and 4.8 × 4.8 × 4.8 mm3 voxel
size. Each data set was compensated separately for attenu-
ation (A), attenuation and collimator-detector response
(AR) and attenuation, collimator-detector and scatter
(ARS). Attenuation and scatter correction (AS) was not im-
plemented, because the convolution-based forced detection
scatter correction method inherently includes collimator
and detector modelling. We think that omitting collimator-
detector modelling for primary photons but applying it for
scatter photons is illogical. Post-filtering was not applied to
any of the data presented in this study. The reconstruction
methods used in this work were implemented into the
reconstruction engine of a commercially available recon-
struction package, HERMES HybridRecon version 1.1
(HERMES Medical Solutions AB, Stockholm, Sweden).
Phantoms
Torso phantom
A RSD Alderson phantom (torso phantom) was modi-
fied to include nine spherical inserts modelling tumours
and two lung density structures, in order to evaluate the
accuracy of the reconstruction methods for inhomogen-
eous density conditions. Six of the inserts were part of
the NEMA image quality phantom, and three were
produced in-house. The inserts were filled with 177Lu so-
lution and placed into the torso phantom. Two identical
inserts (Q2 and Q3) were placed next to the lungs, and
others were placed in the abdomen (Table 1). The right
non-perfusable lung had density of 0.3 g/cm3. The left
lung was an open-cell foam type with low 177Lu activity
filling with a density of 0.3 g/cm3. The volumes of the
right and left lung shells were 1134 and 907 cm3,
respectively (Fig. 1).
After inserting lung and spherical inserts, the phantom
was filled with 177Lu activity to make imaging and analysis
processes more representative of patient studies. The
inserts and left lung concentrations were 30 and 1.7 times
greater than the background, respectively. The total activ-
ity in the phantom was 806 MBq during imaging.
Calibration phantom
The SPECT/CT scanner was calibrated using a calibration
phantom as suggested in MIRD Pamphlet no. 23 [10]. A
bottle (diameter 6.6 cm, height 15.3 cm and volume of
525 cm3) was filled with homogeneous 177Lu solution with
an activity concentration of 0.45 MBq/cm3, and it was
placed inside the cylindrical body of the Jaszczak phantom
filled with water. For each reconstruction parameter set, a
VOI was drawn manually over the bottle based on the
dimensions of the bottle and the CT images. The volumet-
ric sensitivity Ŝvol (kBq/ml) of the SPECT/CT system was
determined as reported by Sanders et.al [12]. During the
study, the Ŝvol values were used to convert torso phantom
and patient SPECT images to activity concentration
distributions.
Patient data
SPECT/CT data of ten different patients were selected
randomly and retrospectively from over 100 who under-
went treatment with 177Lu-DOTATATE, at the Helsinki
University Hospital, Cancer Center between 2011 and
2015. Patients were diagnosed with progressive metastatic
neuroendocrine tumour (grades I–II). The ten selected
patients were treated with infusion of 177Lu-DOTATATE
(range of activity being from 3.4 to 8.1 GBq) incorporated
with kidney protective amino acid infusion. For each three
successive SPECT/CT studies were acquired at 24, 48 and
168 h after the infusion and were reconstructed for this
project in order to study time-activity curves (TACs). The
patient data is summarized in Table 2.
Table 1 The volume and activities as well as the locations of
the tumour inserts in the torso phantom
Label Volume (cm3) Activity (MBq) Location in phantom
Q1 104.4 105.2 Abdomen
Q2 30.3 31.2 Next to active left lung
Q3 30.3 30.4 Next to non-active right lung
Q4 26.1 27.2 Abdomen
Q5 10.8 11.9 Abdomen
Q6 5.5 5.8 Abdomen
Q7 2.6 2.7 Abdomen
Q8 1.2 1.2 Abdomen
Q9 0.4 0.5 Abdomen
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Data analysis and absorbed dose calculations
Nine spherical VOIs were delineated based on the insert
volumes and physical boundaries seen in the CT images.
Sizes of the delineated volumes are shown in the Table 1.
The activity concentration measured using the VOIs was
evaluated using a concentration recovery coefficient
(cRC), which was defined as:
cRC ¼
Rinsert
V insert S^ vol
 
Cinsert
; ðð1ÞÞ
where Rinsert is the count density within the defined
VOI, Vinsert is the VOI volume and Cinsert is the true
concentration in the insert. cRC was calculated for each
insert and each compensation method.
The data for each patient was reconstructed the same
way as the phantoms (15 iterations, 16 subsets) using A,
AR and ARS compensation methods. All the recon-
structed images were co-registered to the 24-h ARS-
reconstructed SPECT image using mutual information-
based co-registration algorithm. The registrations were
each visually verified. CT-based VOIs were drawn using
the physical boundaries of each kidney, excluding the
renal pelvis (Fig. 2). TACs were produced based on
image statistics. A mono-exponential function y(t) =A0e
− λt) was fitted to the TACs, and the effective half-life
Table 2 Patient data characteristics
Subject Activity
(GBq)
SPECT/CT imaging time (h) Delineated kidney VOI volumes (ml)
1. 2. 3. Left Right
P1 7.5 25 52 173 140 132
P2 8.1 25 120 168 281 285
P3 7.2 24 47 168 165 149
P4 7.3 24 45 168 287 270
P5 6.0 33 110 158 137 131
P6 3.7 38 133 181 182 178
P7 8.0 27 117 164 193 154
P8 8.0 28 69 164 176 148
P9 8.1 23 120 168 115 127
P10 4.1 24 71 146 162 134
Fig. 1 A torso phantom (left) and nine spherical inserts (right). Seven of the inserts (Q1, Q4–Q9) are located in the abdomen. Two of the inserts
(Q2 and Q3) were located next to the lungs under the sternum
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T eff ¼ ln2λ was calculated using the decay constant λ,
obtained from the exponential fit.
The total number of decays within the kidney volume
was determined as an analytical integral of the fitted
exponential function from the time of injection (t = 0) to
infinity. The total number of decays was converted to
absorbed dose by taking into account only the self-dose
produced by electrons [5]. The absorbed dose estimates,
D, were compared between compensation method
combinations.
Results
The torso phantom study
The cRC results for A, AR and ARS compensation combi-
nations as a function of the insert volume are shown in
Fig. 2. From this figure, we can see how cRC is dependent
on the size of the insert because of the limited spatial reso-
lution of the SPECT system. Since the collimator-detector
response compensation method can partly compensate for
the resolution loss the dependence gets weaker as more
compensation methods are applied during reconstruction.
The ARS method produced the highest recovery values
for all spheres; the gain was dependent on the insert size
and ranged from 200 % for small inserts to 35 % for the
largest inserts when compared to A method. None of the
methods could recover the true concentration (cRC = 1)
for any of the inserts, because VOIs were drawn based on
the CT image and physical boundaries and no partial
volume correction was attempted.
Patient data
Representative transverse SPECT/CT slices reconstructed
using A, AR and ARS compensation methods are shown
in Fig. 3. The samples are from patients 2 and 3 who had
markedly different amounts of activity accumulation in
the liver as a result of metastases in patient 2. Slices
reconstructed with A were quite noisy, because no post-
filtering was applied after reconstruction. The use of post-
reconstruction filtering would have made these images
visually more appealing but would have also blurred
images and reduced spatial resolution. Slices produced
with AR and ARS are significantly smoother than the A
images due to the collimator-detector response compen-
sation method.
The effective half-lives and absorbed dose estimates
are shown in Fig. 4. There was no clear trend on how
effective half-life depended on the different compensa-
tion methods. On average, AR and ARS produced 3 and
4 % lower effective half-lives than A. On the other hand,
AR method produced on average 15 and 20 % and ARS
19 and 25 % higher higher absorbed doses to the right
Fig. 2 cRC for A, AR and ARS methods as a function of spherical
insert volume
Fig. 3 Representative transverse SPECT/CT slices reconstructed using A, AR and ARS compensation methods of P2 and P3 subjects treated
with 177Lu-DOTATATE
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and left kidneys than A due to systematically higher
activity estimates at different acquisition time points.
There was only one patient case (P2 right kidney) where
AR and ARS methods produced smaller absorbed dose
estimates than method A. This can be explained partly
by the better resolution due to collimator compensation
method and partly by scatter correction which both
helped to reduce spill over from the highly metastatic
liver to the right kidney (Fig. 3).
Discussion
In this study, we have validated the quantitative accuracy
of our reconstruction package for 177Lu using an an-
thropomorphic phantom. We determined cRC values
from nine spherical sources with varying sizes using differ-
ent compensation method combinations applied during
reconstructions. Applying collimator-detector response
compensation dramatically improves cRC compared with
the attenuation corrected only images. In addition to the
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Fig. 4 Box plots of effective half-live (above) and absorbed dose estimates (below) to the right and left kidneys for ten different patient cases. The
full triangles indicate average values of the set and the whiskers are extended to minimum and maximum data values (Spear style)
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collimator-detector response compensation method, the
MC simulation-based scatter correction method improved
quantitation accuracy even more, especially for small
sources.
Our results are comparable with recently published
studies [12, 14]. In a recent study, Sanders et al. reported
the cRC being around 80 % for the 16-ml spherical
source, while we found cRC to be 75 and 85 % for
sources with size of 11.5 and 26.2 ml, respectively
(Fig. 2). For the small inserts like Q7 with volume of
2.6 ml, the ARS method produced cRC of 70 %, which is
as high as Sanders et.al reported for the sources with
volume from 4 to 8 ml.
From the patient data, we found a similar trend in
absorbed doses as with the cRC values: ARS produced
the highest absorbed dose estimates between the
methods evaluated in this study due to systematically
higher activity estimates at every acquisition time point.
For example in eight out of ten cases, ARS produced
over 20 % higher estimated absorbed doses into the left
or right kidney than method A, and in patient P9 case,
ARS produced up to 40 % higher estimated dose than
method A. In general, the absorbed doses to kidneys
ranged from 1.3 to 5 Gy. Similar dose ranges have been
reported earlier [2, 3]. Considering 23 Gy absorbed dose
limit to the kidneys derived from external radiotherapy,
the difference between reconstruction methods can be
considered to be clinically relevant. In other words, for
an individual patient, the number of treatment cycles
can depend on what reconstruction method has been
used during dose calculations.
Frequently, in patients with liver metastatic neuroendo-
crine tumours, the distinction between the right kidney and
liver metastases’ 177Lu-DOTATATE activity distributions is
challenging to make due to the poor spatial resolution of
SPECT systems. In this study, we have shown how the
collimator-detector compensation method can help with
these kinds of cases. In patient P2, ARS produced 24 %
smaller absorbed doses to the right kidney than A, but it
was clearly due to an improved distinction between kidney
and liver activity distributions and reduced spill in from
liver volume to the kidney.
In our study, we have delineated the VOIs based on
CT image and tracked the physical boundaries of either
inserts or kidneys. The method is arguably cumbersome
and sensitive to partial volume effect (PVE). Some of the
authors of previous studies have used a so-called a small
VOI method [7], where a small VOI is used to sample
activity within the whole kidney. The small VOI method
is easy to implement and is at least justifiable for cases
like the patient P2, where a clear distinction between
activity distributions is difficult to make. However, the
small VOI gives a limited sample of the kidney’s activity
distribution, and thus, the dose calculation is carried out
using a small and manually selected representative VOI
statistics. Because the selection of the small VOI is not
always unambiguous, in clinical practice, dose calcula-
tion is compromised, for example, to represent only the
maximum dose of the kidney, and it does not take activ-
ity heterogeneity into account. In addition to this, to
carry out the patient-specific dose calculation, the kidney
masses should be delineated patient specifically; thus,
whole kidney delineation was preferred in our study.
Conclusions
Applying attenuation, collimator-detector and Monte
Carlo scatter compensation methods (ARS) improved cRC
especially in small-sized sources which might aid tumour
dosimetry for 177Lu PRRT treatments. From the patient
data, we observed that 177Lu-DOTATATE half-life esti-
mates did not apparently depend on reconstruction com-
pensation methods.
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